<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03781882</url>
  </required_header>
  <id_info>
    <org_study_id>PRP surgical wounds</org_study_id>
    <nct_id>NCT03781882</nct_id>
  </id_info>
  <brief_title>Local Injection of PRP During Repair of Disrupted Surgical Wounds</brief_title>
  <official_title>Local Injection of Autologous Platelet Rich Plasma During Repair of Disrupted Surgical Wounds at Obstetrics and Gynecology Department: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with disrupted wounds will either managed as usual or managed by Platelet rich
      plasma local infiltration in the wound edges
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients with disrupted surgical wounds will be cleansed, debrided and closed with
      infiltration of platelet rich plasma in one group and the other group will be closed without
      infiltration of Platelet rich plasma
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All cases with disrupted surgical wounds admitted at Obstetrics and Gynecology departments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients were not allowed to know allocations</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Complete wound healing</measure>
    <time_frame>30 days</time_frame>
    <description>time needed for complete wound closure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Time during which patient is admitted</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure of complete wound healing</measure>
    <time_frame>30 days</time_frame>
    <description>No complete closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need fo tertiary suture</measure>
    <time_frame>30 days</time_frame>
    <description>need to re-operate the case again</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Role of Platelet Rich Plasma in Wound Healing</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients in this group will be manged as usual with infiltration of platelet rich plasma in thee wound edges during closure of the wounds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients in this group will be managed by repair of wounds without infiltration of platelet rich plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Platelet rich plasma infiltration in the wound edges</intervention_name>
    <description>platelet rich plasma will be injected in the wound edges</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Closure of wound without platelet rich plasma infiltration</intervention_name>
    <description>No infiltration of platelet rich plasma is done</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Disrupted surgical wounds after cesarean sections and other gynecological operations

          -  Body mass index 18-25

          -  Hemoglobin &gt; 10.5gm/dl

          -  Albumin &gt;3.5gm/dl

        Exclusion Criteria:

          -  Medical disorders asDiabetes mellitus (DM), Liver disease or systemic lupus
             erythymatosus (SLE)

          -  Patient on corticosteriod therapy

          -  Thrombocytopenia

          -  Coagulation disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ayman Shehata Dawood</name>
      <address>
        <city>Tanta</city>
        <zip>31111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Ayman S Dawood, MD</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>Platelet rich plasma</keyword>
  <keyword>disrupted wounds</keyword>
  <keyword>Obstetrics and Gynecology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share unidentified data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>30 days</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

